Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

Rhea-AI Summary

Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29 in Nantucket, MA. CEO Mark Foley is scheduled to present on September 28 at 9:00 A.M. EST. A live audio webcast will be accessible from the Investor Relations section of the company's website and a replay will be available for 30 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including products like DAXXIFY™ and a biosimilar to BOTOX®.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Guggenheim Nantucket Therapeutics Conference, taking place September 27 – 29, in Nantucket, MA.

Chief Executive Officer, Mark Foley, is scheduled to present on Wednesday, September 28, at 9:00 A.M. EST.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance

Revance is a commercial stage biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DaxibotulinumtoxinA for Injection in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com or connect with us on LinkedIn.

“Revance” and the Revance logo and OPUL are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005315/en/

Media

Revance Therapeutics, Inc.:

Sara J. Fahy

Media@revance.com

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 626-589-1007

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Source: Revance Therapeutics, Inc.

FAQ

What dates will Revance Therapeutics participate in the Guggenheim Nantucket Therapeutics Conference?

Revance Therapeutics will participate in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29.

When is Mark Foley's presentation at the Guggenheim Nantucket Therapeutics Conference?

Mark Foley's presentation is scheduled for September 28 at 9:00 A.M. EST.

How can I access the live audio webcast of Revance's presentation?

The live audio webcast can be accessed from the Investor Relations section of Revance's website.

What are some key products offered by Revance Therapeutics?

Revance offers products including DAXXIFY™ and the RHA® Collection of dermal fillers.

Is Revance Therapeutics developing a biosimilar to BOTOX®?

Yes, Revance has partnered with Viatris Inc. to develop a biosimilar to BOTOX®.